Literature DB >> 15607953

Neuroprotective effects of the synthetic cannabinoid HU-210 in primary cortical neurons are mediated by phosphatidylinositol 3-kinase/AKT signaling.

Francisco Molina-Holgado1, Emmanuel Pinteaux, Laura Heenan, Jonathan D Moore, Nancy J Rothwell, Rosemary M Gibson.   

Abstract

Cannabinoids (CBs) are neuroprotective in vivo and in vitro, but the mechanisms of their actions are unknown. The aim of this study was to elucidate the signaling pathways that mediate the protective effect of CBs on primary cultured neurons. The neurotoxin S-AMPA induced significant death of rat primary cortical neurons, which was inhibited by the CB agonist HU-210. Antagonists selective for CB(1) or CB(2) receptors (AM 281 or AM 630, respectively) reversed the neuroprotective effect of HU-210 on S-AMPA-induced cell death. HU-210 triggered activation of AKT, but not activation of the ERK1/2, JNK or p38 signaling pathways. The phosphatidylinositol 3-kinase (PI 3-K) inhibitors LY294002 and wortmannin prevented phosphorylation of AKT in response to HU-210, and reversed the neuroprotective effect of HU-210 on S-AMPA-induced excitotoxicity. Thus the PI 3-K/AKT signaling pathway mediates the neuroprotective effect of exogenous cannabinoids such as HU-210 in primary CNS neurons.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15607953     DOI: 10.1016/j.mcn.2004.09.004

Source DB:  PubMed          Journal:  Mol Cell Neurosci        ISSN: 1044-7431            Impact factor:   4.314


  28 in total

1.  Equipotent inhibition of fatty acid amide hydrolase and monoacylglycerol lipase - dual targets of the endocannabinoid system to protect against seizure pathology.

Authors:  Vinogran Naidoo; David A Karanian; Subramanian K Vadivel; Johnathan R Locklear; JodiAnne T Wood; Mahmoud Nasr; Pamela Marie P Quizon; Emily E Graves; Vidyanand Shukla; Alexandros Makriyannis; Ben A Bahr
Journal:  Neurotherapeutics       Date:  2012-10       Impact factor: 7.620

2.  AKT1 moderation of cannabis-induced cognitive alterations in psychotic disorder.

Authors:  Ruud van Winkel; Nico J M van Beveren; Claudia Simons
Journal:  Neuropsychopharmacology       Date:  2011-07-20       Impact factor: 7.853

3.  Inhibitor of Endocannabinoid Deactivation Protects Against In Vitro and In Vivo Neurotoxic Effects of Paraoxon.

Authors:  Karen L G Farizatto; Sara A McEwan; Vinogran Naidoo; Spyros P Nikas; Vidyanand G Shukla; Michael F Almeida; Aaron Byrd; Heather Romine; David A Karanian; Alexandros Makriyannis; Ben A Bahr
Journal:  J Mol Neurosci       Date:  2017-08-12       Impact factor: 3.444

4.  Dual neuroprotective and neurotoxic effects of cannabinoid drugs in vitro.

Authors:  Anastasia Bologov; Mikhal Gafni; Ora Keren; Yosef Sarne
Journal:  Cell Mol Neurobiol       Date:  2010-11-04       Impact factor: 5.046

Review 5.  Remote neurodegeneration: multiple actors for one play.

Authors:  Maria Teresa Viscomi; Marco Molinari
Journal:  Mol Neurobiol       Date:  2014-01-19       Impact factor: 5.590

6.  Reactive oxygen species and p38 phosphorylation regulate the protective effect of Delta9-tetrahydrocannabinol in the apoptotic response to NMDA.

Authors:  Jia Chen; Stacie L Errico; William J Freed
Journal:  Neurosci Lett       Date:  2005-12-02       Impact factor: 3.046

Review 7.  The analgesic potential of cannabinoids.

Authors:  Jaseena Elikkottil; Jaseena Elikottil; Pankaj Gupta; Kalpna Gupta
Journal:  J Opioid Manag       Date:  2009 Nov-Dec

Review 8.  Marijuana, Spice 'herbal high', and early neural development: implications for rescheduling and legalization.

Authors:  Delphine Psychoyos; K Yaragudri Vinod
Journal:  Drug Test Anal       Date:  2012-08-13       Impact factor: 3.345

Review 9.  Roles of transient receptor potential vanilloid subtype 1 and cannabinoid type 1 receptors in the brain: neuroprotection versus neurotoxicity.

Authors:  Sang R Kim; Young C Chung; Eun S Chung; Keun W Park; So Y Won; E Bok; Eun S Park; Byung K Jin
Journal:  Mol Neurobiol       Date:  2007-06       Impact factor: 5.590

10.  The cannabinoid CB2 receptor as a target for inflammation-dependent neurodegeneration.

Authors:  John C Ashton; Michelle Glass
Journal:  Curr Neuropharmacol       Date:  2007       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.